Biocartis Group NV

Equities

BCART

BE0974281132

Medical Equipment, Supplies & Distribution

Market Closed - Euronext Bruxelles Other stock markets 11:35:06 2023-09-22 am EDT			5-day change	1st Jan Change
0.29 ^EUR	+1.05%		-.--%	-.--%

May. 06	Biocartis, Merck KGaA Expand Cancer Biomarker Testing Collaboration into MENA Region	MT
2023	Biocartis Group NV Presents Four Abstracts Showing Excellent Data for Idylla at European Society of Molecular Oncology Congress	CI

Biocartis Establishes US Subsidiary; Appoints Vishal Sikri as General Manager for US Operations

April 04, 2017 at 02:02 am EDT

Biocartis Group NV announced the establishment of its US subsidiary, Biocartis US Inc., and the appointment of Vishal Sikri as its US General Manager. Both are important next steps in the execution of Biocartis' US strategy following the announced commercialization agreement with Thermo Fisher Scientific Inc. in November 2016.

The company announced the appointment of Vishal Sikri as the General Manager for its US operations. Before joining Biocartis, he was Managing Director and VP Commercial Operations responsible for all global commercial operations of Sysmex Inostics, the molecular diagnostics' division of Sysmex Corporation.

Latest news about Biocartis Group NV

Biocartis, Merck KGaA Expand Cancer Biomarker Testing Collaboration into MENA Region	May. 06	MT
Biocartis Group NV Presents Four Abstracts Showing Excellent Data for Idylla at European Society of Molecular Oncology Congress	23-10-20	CI
Biocartis, APIS Assay Technologies to Commercialize Estrogen Receptor-positive Mutations Kit	23-10-12	MT
Biocartis Group NV Announces Expansion of Its Collaboration with APIS Assay Technologies Ltd to Commercialize the APIS ESR1 Mutations Kit	23-10-12	CI
Biocartis Winding Down Begins with Creditors' Takeover of Operating Units	23-09-26	MT
Biocartis Group NV Reports Earnings Results for the Half Year Ended June 30, 2023	23-09-26	CI
Biocartis Appoints New Medical Advisory Board of Renowned Practice Leaders	23-08-28	CI
Biocartis, Eli Lilly to Develop Diagnostics System to Identify Therapy-eligible Lung Cancer Patients	23-08-10	MT
Biocartis Group NV Partners with Lilly to Explore Biomarker Testing for NSCLC Patients Using the Idylla? Platform	23-08-10	CI
Molecular Diagnostics Company Biocartis Group Names New CFO	23-07-18	MT
Biocartis Group NV Appoints George Cardoza as Chief Financial Officer, Effective 7 August 2023	23-07-18	CI
Biocartis Group NV Appoints George Cardoza as Head of Service Delivery, Effective 7 August 2023	23-07-18	CI
Biocartis CFO to Depart in August	23-06-06	MT
Biocartis Group NV Announces Resignation of Jean-Marc Roelandt as CFO	23-06-05	CI
Certain ordinary shares of Biocartis Group NV are subject to a Lock-Up Agreement Ending on 2-JUN-2023.	23-06-01	CI
Biocartis, HiloProbe Enter Commercialization Partnership for Colorectal Cancer Test	23-05-09	MT
Molecular Diagnostics Group Biocartis Names New CEO	23-04-12	MT
Biocartis, APIS Assay Technologies to Develop Breast Cancer Test	23-04-04	MT
Biocartis Group NV and APIS Assay Technologies Sign Collaboration to Develop and Commercialise a Breast Cancer Subtyping Test on the Idylla Platform	23-04-04	CI
Biocartis' Colorectal Cancer Tumor Test Secures US FDA Approval	23-03-02	MT
Biocartis Group NV Announces the US FDA 510(K) Clearance for the Idylla™ MSI Test	23-03-02	CI
Transcript : Biocartis Group NV, Q4 2022 Earnings Call, Feb 23, 2023	23-02-23
Biocartis Group NV Reports Earnings Results for the Full Year Ended December 31, 2022	23-02-23	CI
Biocartis Group Nv Provides Financial Guidance for the Fiscal Year 2023	23-02-23	CI
Biocartis Group NV Announces Change in Board Composition	23-02-22	CI

Chart Biocartis Group NV

Duration

Period

More charts

Company Profile

Biocartis Group NV specializes in the development of molecular diagnostic systems. Especially for the treatment of cancers and infectious diseases, the products ensure the analysis of biomolecules associated with risk factors, early detection, treatment selection and monitoring of disease. The group has the Idylla system to deliver results within a period of between 35 to 150 minutes. Net sales by source of income are mainly distributed between products sales (78.3%) and sale of collaboration services (19.3%; especially research and development services).

Sector

Medical Equipment, Supplies & Distribution

Calendar

2024-09-04 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Annual profits - Rate of surprise

Company calendar

Sector Medical Equipment

	1st Jan change	Capi.
BIOCARTIS GROUP NV	-.--%	29.58M
SHOCKWAVE MEDICAL, INC.	+72.98%	12.38B
PENUMBRA, INC.	-20.40%	7.81B
MASIMO CORPORATION	+6.24%	6.72B
JIANGSU YUYUE MEDICAL EQUIPMENT & SUPPLY CO., LTD.	+12.78%	5.39B
APT MEDICAL INC.	+38.73%	5.03B
GETINGE AB	-16.79%	4.72B
ASAHI INTECC CO., LTD.	-22.01%	4.06B
INARI MEDICAL, INC.	-29.57%	2.68B
NOVOCURE LIMITED	+52.38%	2.59B

Medical Equipment